Although Bordetella pertussis contains and transcribes loci encoding type III secretion system (TTSS) homologues, expression of TTSS-associated proteins has been reported only for non-laboratory-adapted Irish clinical isolates. Here we confirm such a result for clinical isolates obtained from patients treated in Argentinean hospitals. Moreover, we demonstrate that the expression of TTSS-associated proteins is independent both of the year in which the isolate was obtained and of the types of polymorphic alleles for other virulence factors but is dependent on environmental growth conditions. Interestingly, we observed that TTSS-associated protein expression is lost after successive in vitro passages but becomes operative again when bacteria come into contact with the host. This in vivo activation of TTSS expression was observed not only for clinical isolates previously adapted to the laboratory after successive in vitro passages but also for vaccine strains that did not express the system in vitro. The reversibility of TTSS expression, demonstrated by its switching off-on when the bacterium comes into contact with the host, appears to be an adaptive response of this pathogen.
Many bacteria can modulate host cell traits not only by secreting proteins into the extracellular environment but also by translocating them directly into the interiors of host cells. One of the most widespread means for translocating bacterial proteins into host cells is the type III secretion system (TTSS). This system, composed of 20 to 25 proteins, is responsible for the transport of bacterial proteins that act as powerful "effectors" and take control of host cells by hijacking their intracellular machinery (18) . The TTSS has been identified in many animal pathogens, such as Yersinia spp., Salmonella spp., Shigella spp., enteropathogenic and enterohemorrhagic Escherichia coli (e.g., O157:H7), Pseudomonas aeruginosa, Vibrio parahaemolyticus, Bordetella spp., and Chlamydia spp. (6, 16, 21, 38) . Certain bacteria, such as Salmonella enterica serovar Typhimurium, Yersinia pestis, and Yersinia enterocolitica, encode more than one TTSS (6, 16) . The distribution of the TTSS is not limited exclusively to animal pathogens; it has also been identified in plant pathogens and certain endosymbiotic bacteria (22, 40, 42) .
Although the sequences of many components of the TTSS apparatus used to transport effectors are conserved among bacteria, and some of these components are also functionally interchangeable, the target cells respond to this kind of "injection" in different ways depending on the system involved (5, 7, 8, 17) .
It is noteworthy that the effector proteins of the TTSS not only can be translocated but also can be secreted into the extracellular medium under appropriate laboratory conditions. For example, the Ysc TTSS, one of the two TTSSs of Yersinia, can secrete effector proteins into the extracellular environment when bacteria are grown at 37°C in a medium containing a low concentration of calcium (29) . Shigella can also secrete effector proteins when it is grown in the presence of the dye Congo red (33) . Interestingly, in the case of Bordetella pertussis, a pathogen that causes a resurgent respiratory disease called whooping cough or pertussis, the conditions for secretion by the TTSS seem to differ between the circulating clinical bacterial population and laboratory-adapted strains (12) . That is, in vitro expression of one of the known TTSS effector proteins, Bsp22, was detected in a significant proportion of Irish clinical isolates but not in common laboratory-adapted strains of B. pertussis. In parallel, by a comparative proteomic strategy, we had already obtained evidence showing that a TTSS was expressed in one Argentinean clinical isolate but not in a Tohama phase I strain (1) . These findings are important not only because they show new aspects of the regulation of TTSS expression but also because they represent the first data on the functionality of the system in B. pertussis. Although the TTSS gene cluster has been found, and designated the bsc locus (11, 45) , in three species of the Bordetella genus, B. pertussis, B. parapertussis, and B. bronchiseptica, the functionality of the system has been described only for B. bronchiseptica (27) . Through this system B. bronchiseptica secretes Bsp22 as the most abundantly expressed TTSS protein during in vitro growth. Bsp22 is highly immunogenic and has the ability to confer protection against B. bronchiseptica infection (28) . This protein also appears to play a role in mediating persistent infection of the lower respiratory tract and is required for TTSS-mediated cytotoxicity toward eukaryotic cells (28, 44) .
The recently demonstrated expression of TTSS proteins in B. pertussis clinical isolates but not in strains adapted to laboratory culture conditions (12) , such as vaccine strains, is an interesting phenomenon, which should be more thoroughly analyzed not only in the context of B. pertussis evolution in vitro but also in the context of the reemergence of the disease. Thus, we analyze here whether the findings of Fennelly et al. (12) can also be extended to other, geographically unrelated clinical isolates and to those with different genotypes. Moreover, we evaluate the hypotheses proposing that the differential expression of the TTSS between vaccine strains and clinical isolates relies on bacterial adaptation to in vitro growing conditions. Both aspects were addressed by performing assays comparing reference and vaccine strains with clinical isolates from Argentina exhibiting different allelic variants of pertactin (Prn) and pertussis toxin (Ptx).
MATERIALS AND METHODS
Bacterial strains and culture conditions. The Bordetella strains and clinical isolates used in this study are listed in Table 1 . B. pertussis clinical isolates were recovered from the nasopharyngeal aspirates of infants with whooping cough. Clinical samples were collected in Argentina during the years 1969 to 2007. Strains and isolates from glycerol stocks were cultured on Bordet-Gengou agar (BGA; Difco) supplemented with 1% glycerol and 10% (vol/vol) defibrinated sheep blood and were incubated at 36°C for 3 days. Then, from BGA hemolytic colonies (a marker of the virulent state of the bacteria), bacteria were replated in the same medium for 24 h in order to obtain B. pertussis biomass retaining virulent characteristics. To obtain supernatant proteins, subcultures were grown in Stainer-Scholte (SS) liquid medium (34) . Mutants were selected on BGA or SS medium supplemented with gentamicin (Gm; 10 mg ml 21 ) and kanamycin (Km; 75 mg ml 21 ). To modulate virulence factor expression, bacteria were grown in SS medium supplemented with 40 mM MgSO 4 at 36°C.
For passage experiments, strains were grown at 36°C on BGA with 10% defibrinated sheep blood until individual colonies were well-defined, and a single colony was streaked onto a fresh plate.
Escherichia coli strains TOP10 and BL21(DE3) (both from Invitrogen) were cultured in Luria-Bertani (LB) medium supplemented, when appropriate, with ampicillin (Ap) and Km, at final concentrations of 100 and 50 mg/ml, respectively.
PCR amplification, cloning, and expression of recombinant His 6 -Bsp22. Primers bsp22F (59-CACCATGAGCATTGATCTCG-39) and bsp22R (59-TTGCTC CTGCATGGAATACT-39) were used to amplify the open reading frame (ORF) of Bsp22 from B. pertussis Tohama I. The PCR assay was conducted in a final volume of 20 ml with 0.5 U of Platinum Pfx polymerase (Invitrogen). The amplified product of 727 bp was cloned first into the pENTR/SD/D-TOPO entry vector and then into the Gateway pDEST17 destination vector according to the manufacturer's instructions (Invitrogen). The recombinant clones were confirmed by PCR and were sequenced. The pDEST17:bsp22 vector was transformed first into TOP10 competent E. coli cells and then into BL21 Star (DE3) host expression cells. For Bsp22 expression, a selected clone was grown in LB medium containing ampicillin (100 mg ml 21 ). When the cell culture reached an optical density at 600 nm (OD 600 ) of ;0.6, protein expression was induced with isopropyl-b-D-thiogalactopyranoside (IPTG) at a final concentration of 1 mM, and incubation was continued for another 3 h. E. coli cells were harvested and resuspended in Laemmli buffer (26) , and the total proteins in soluble whole lysates were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Electrophoresis was performed at room temperature and constant voltage. Molecular weight was estimated by means of the GE calibration kit, and proteins resolved on gels were visualized by using a Coomassie blue staining method.
Purification of recombinant His 6 -Bsp22. For His 6 -Bsp22 purification, recombinant E. coli DE3 cells obtained from 100 ml of IPTG-induced cultures were resuspended in 4 to 8 ml of denaturing lysis buffer (Invitrogen). The recombinant protein was solubilized, and bacterial cells were disrupted by sonication (30-s pulses with 30-s intervals for 5 min). After centrifugation, the resultant supernatant was loaded onto Ni-nitrilotriacetic acid (NTA) columns (Invitrogen) equilibrated in denaturing lysis buffer (Invitrogen). The recombinant protein was purified under denaturing conditions (buffers used contained 8 M urea at different pH values ranging from 7.9 to 4.0). The purification steps were performed according to the manufacturer's protocols. Fractions containing recombinant His 6 -Bsp22 were pooled and concentrated 16-fold using an Amicon Ultra-4 10K centrifugal filter device (Millipore). The final product was judged to be pure by SDS-PAGE. Fractions containing purified protein were dialyzed at 4°C against phosphate-buffered saline (PBS) to remove urea from the preparation and were stored at 220°C until use. The identity of the expressed protein and its molecular weight were confirmed by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. The protein concentration of purified His 6 -Bsp22 was determined by the Bradford method, with bovine serum albumin as a standard (3).
Production of a polyclonal serum against His 6 -Bsp22. To obtain specific sera against His 6 -Bsp22, 3 mice obtained from the Instituto Biológico Argentino (Biol. SAIC, Argentina) were immunized intraperitoneally twice, at intervals of 14 days, with 5 mg of the purified recombinant protein each time. Al(OH) 3 was used as an adjuvant. Fourteen days after the last immunization, mice were bled, and the serum was prepared in order to assess the presence of specific circulating antibodies against His 6 -Bsp22 by immunoblotting.
B. pertussis Dbsp22 mutant strain construction. Gentamicin-resistant Dbsp22 derivatives of B. pertussis Bp106 (Bp106 Dbsp22) were constructed as follows. Two single-stranded oligonucleotide primers were designed on the basis of the bsp22 sequence: bsp22 RT F (59-AACTCCTCACGGCTCAAATG-39) and bsp22 RT R (59-ACGGTGGTGTAGGCACTTTC-39). Using these primers and Taq DNA polymerase (0.5 U), we accordingly amplified a 346-bp fragment corresponding to an internal sequence of the bsp22 gene by PCR. This PCR product was cloned into the shuttle plasmid pGEM-T Easy (Ap r lacZ). After ligation, a recombinant fragment from this plasmid was released with EcoRI and was cloned into the EcoRI site of the Bordetella suicide plasmid pG18mob (Gm r ) (25) . The recombinant suicide plasmid pG18mob:bsp22 was transformed into electrocompetent Bp106 cells, which were thereafter selected for single genetic crossovers on BGA supplemented with 10 mg/ml gentamicin. A gentamicinresistant single recombinant of B. pertussis Bp106 was screened by PCR using M13 and the bsp RT22 F/bsp RT22 R primers for the presence of the expected DNA structure and was also analyzed by immunoblotting for Bsp22 expression.
RNA isolation and RT-qPCR. Total RNA from mid-log-phase bacterial cultures was isolated using a commercial RNAspin Mini RNA isolation kit (GE Healthcare) according to the manufacturer's protocols. Reverse transcriptionquantitative PCR (RT-qPCR) was performed using 300 ng of total RNA and Moloney murine leukemia virus reverse transcriptase (Promega). The resulting cDNA was amplified in triplicate using a SYBR green PCR assay (Bio-Rad Laboratories, Hercules, CA), and products were detected on an iQ5 cycler (Bio-Rad). PCR samples were incubated for 4 min at 95°C, followed by 40 amplification cycles with 30 s of annealing/extension at 60°C and 15 s of denaturation at 95°C. For analysis of bscN and bscC gene transcription, the following primers were used: bscNF (59-CATGCCCACAAGTTCTATCC-39)/bscNR (59-GACCGAGTCCATCAGAAAAA-39) and bscCF (59-CCTTGATCGTGCAGG ATATT-39)/bscCR (59-GGGTGCGAATGTAGAAGGTA-39). For analysis of bsp22 gene transcription, the bsp RT22 F and bsp RT22 R primers, described above, were used. PCR specificity was checked by melting curves. recA transcription was used as a normalizer with primers recAF (59-AAGACCACGCTCACGCTGCA GGTCA-39) and recAR (59-ATCAGCAGGTCGGTCAGGTTGACGC-39). The relative mRNA expression levels of each gene in each sample were calculated using the comparative threshold cycle (C T ) method (35) . The categorical variables were compared by using one-way analysis of variance with a Tukey posttest. A P value of ,0.05 was considered statistically significant. Immunoblot analysis. B. pertussis grown on BGA or SS liquid medium was used for the different preparations. The whole-cell lysate was prepared as described previously (14) . To analyze supernatant fractions of Bordetella spp., bacteria were grown in SS medium in 100 ml of culture inoculated at a starting OD 650 of 0.20. Cultures were harvested for each bacterial strain at the same stage of bacterial growth as determined by OD 650 measurements. Cell-free supernatant fractions obtained after filtering through a 0.22-mm-pore-size polycarbonate filter were precipitated with 10% (wt/vol) trichloroacetic acid at 4°C for 4 h and were then resuspended in sample buffer. Bordetella sp. whole-cell lysates and supernatants were transferred to a polyvinylidene difluoride (PVDF) membrane (Immobilon P; Millipore). For this purpose, SDS-PAGE was performed according to the method of Laemmli (26) using denaturing 15% (wt/vol) SDS-polyacrylamide gels. Proteins separated by SDS-PAGE were transferred to a polyvinylidene difluoride membrane (Immobilon P; Millipore) at a constant voltage (100 V; 1 h) and were then probed either with a polyclonal anti-Bsp22 antibody or with a polyclonal anti-PtxS1 antibody (diluted 1:500), followed by incubation with anti-mouse IgG conjugated with alkaline phosphatase (AP) at a 1:1,000 dilution. Nitroblue tetrazolium (NBT)-5-bromo-4-chloro-3-indolylphosphate (BCIP) was used as the AP substrate according to the manufacturer9s protocol (Promega).
i.n. infection of mice with B. pertussis. Female BALB/c mice, 3 to 4 weeks of age, obtained from the Instituto Biológico Argentino (Biol. SAIC, Argentina) were infected intranasally (i.n.) with 10 7 CFU of B. pertussis strain Tohama I, the Bp106 clinical isolate, or its laboratory-adapted derivative strain (Bp106 after 35 passages) in 50 ml of a PBS suspension. Bacteria from glycerol stocks were cultured on BGA (Difco) supplemented with 1% glycerol and 10% (vol/vol) defibrinated sheep blood and were incubated at 36°C for 3 days. Then the bacteria were replated in the same medium for 24 h, resuspended, and adjusted to approximately 10 8 CFU ml 21 in phosphate-buffered saline. Infections were performed by pipetting the inoculum down into the nostrils. Animals were sacrificed 8 days after infection, and lungs were excised for bacterial recovery as described previously (1) . The expression of Bsp22 in recovered bacteria was evaluated by immunoblotting. At least two independent experiments were performed.
RESULTS AND DISCUSSION
The reemergence of the disease called pertussis has been attributed mainly to waning vaccine-induced immunity and pathogen adaptation (31) . Pathogen adaptation is supported by the antigenic divergence observed between vaccine strains and clinical isolates with respect to several vaccine components, such as pertussis toxin (Ptx) and pertactin (Prn) (10, 14, 23, 30, 31, 39) . In addition to antigenic variation, increased Ptx production has been associated with the resurgence of pertussis. Strains with a novel allele for the ptx promoter (ptxP3) emerged in the 1990s, replacing the resident ptxP1 strains (32) . Sporadically, isolates obtained from pertussis patients do not produce Prn or Ptx (2) .
An interesting recent report demonstrates the secretion of the Bordetella TTSS effector, Bsp22, by a significant number of Irish B. pertussis clinical isolates but not by common laboratoryadapted vaccine strains, such as Tohama I (12) . Despite reports describing the transcription of genes encoding components of the Bordetella bsc TTSS machinery in B. pertussis Tohama I (9, 20, 27) , studies performed before that of Fennelly et al. (12) have failed to demonstrate TTSS effector secretion by B. pertussis either in vitro or in vivo (20, 27) . Fennelly et al. suggested, but did not demonstrate, that B. pertussis might lose the capacity to express TTSS proteins after prolonged in vitro culture (12) . In this work, we extended the analysis of TTSS protein expression to Argentinean clinical isolates and evaluated the previous hypothesis by performing successive in vitro cultures and in vivo infection assays.
As a first step, we corroborated by quantitative PCR that a laboratory-adapted vaccine strain (strain Tohama I) and a clin-ical isolate (Bp106) representative of our bacterial collection transcribe differential levels of mRNA for TTSS-associated genes. In particular, we evaluated bscN, bscC, and bsp22 mRNA levels. Although both strains transcribed the three genes analyzed, Bp106 showed higher mRNA levels than Tohama I, and these differences were most pronounced for the bsp22 gene (Fig. 1 ). Taking these results into account, we decided to measure the expression of the TTSS in clinical isolates by using the effector protein Bsp22 as a marker. To this end, we performed immunoblot assays using a specific serum, obtained from the recombinant His 6 -Bsp22 protein constructed here, whose identity was confirmed by MALDI-TOF spectrometry. The specificity of the anti-Bsp22 serum against the characteristic epitopes of wild-type Bsp22 protein and not against the recombinant protein was evaluated through immunoblot assays using antigens derived from B. bronchiseptica. In particular, we used the cell-free supernatant proteins from B. bronchiseptica CIP 9.73 (Bb9.73) and its derivative BvgA-defective mutant (Bb9.73 DbvgA), which is fixed in the wellknown phenotypic avirulent state (13) . This mutant was employed for the assay because it had already been demonstrated that TTSS is not expressed when the bacterium is in the avirulent phase (27) . We also included in the experiments the supernatant proteins from the Bp106 clinical isolate and its derivative Bsp22-defective mutant (Bp106 Dbsp22), obtained in this work by site-specific insertional mutagenesis (Fig. 2) . As shown in Fig. 2 , the anti-Bsp22 serum recognized a band with the expected molecular size for Bsp22 in the parental Bb9.73 and Bp106 strains but not in either defective mutant (Bb9.73 DbvgA or Bp106 Dbsp22).
For immunoblotting using the specific anti-Bsp22 polyclonal serum, cell-free supernatant proteins from 15 selected B. pertussis clinical isolates in our collection with different genotypic characteristics, obtained during the years 1969 to 2007, were used ( Table 1) . As shown in Fig. 3 , the specific serum reacted against a protein with the expected molecular size of 22 kDa in all clinical isolates assayed, independently of the year of isolation or genotypic characteristics. As expected, this Bsp22-specific antiserum, which recognized the presence of Bsp22 in B. bronchiseptica, did not react with samples obtained from ref- (Fig. 3) . To assess whether the expression of the system in these isolates was lost after they were adapted to in vitro culture conditions, we selected a subset of isolates (Bp106, Bp6901, and Tohama I) to be subjected to 35 successive passages in vitro. In these bacteria, TTSS expression was again assessed by immunoblot assays for the Bsp22 protein ( Fig. 4) . Interestingly, while all the bacteria studied expressed Ptx, TTSS expression was observed only in clinical isolates recently obtained from the host, not in long-term laboratory-adapted cultures (Fig. 4A ). In fact, TTSS expression was already lost at the 5th in vitro passage (Fig. 4B) . In contrast, strain Tohama I, which has been extensively grown through laboratory passages since its isolation in Japan in 1954 (24), did not express Bsp22 protein in any of the culture steps assessed. To establish precisely in which passage the expression of Bsp22 in Bp106 is lost, we performed a new immunoblot assay for passages 1 to 5 (Fig.  5 ). As can be seen in Fig. 5 , Bsp22 expression stops between passages 3 and 4. As a control for all immunoblot assays performed, we included Bsp22 recombinant protein obtained from an engineered E. coli strain constructed by us. These results demonstrating the inability of in vitro cultureadapted bacteria to express the marker Bsp22 raise the question of whether these laboratory species, including the vaccine strain Tohama I, are able to reexpress the TTSS effector Bsp22 when they regain contact with the host. To check this phenomenon, mice were infected with laboratory-adapted or nonadapted bacteria and were sacrificed 8 days after infection in order to test the abilities of the microorganisms recovered from their lungs to express Bsp22. Immunoblot assays using the Bsp22-specific antiserum showed that both laboratoryadapted clinical isolates and the vaccine strain Tohama I were now able to express proteins of the TTSS system ( Fig. 6) .
Taken together, the results presented here not only confirm that the expression of TTSS is a feature of natural B. pertussis Proteins from reference and vaccine strains (A) and from clinical isolates (B) were resolved by 15% (wt/vol) SDS-PAGE, transferred to a PVDF membrane, and probed with a polyclonal serum specific for Bsp22. Samples in panel A were also probed with a polyclonal antiserum specific for subunit S1 of pertussis toxin (Ptx S1 ). Positive controls were purified recombinant His 6 -Bsp22 and Ptx S1 proteins, as well as samples obtained from B. bronchiseptica strain 9.73 (Bb9.73) and the clinical isolate Bp106.
infection but also demonstrate the reversibility of the expression system depending on whether the bacteria do or do not come into contact with the host. Even though this work was not intended to elucidate the molecular mechanism of the phenomenon demonstrated, some evidence indicates that B. pertussis, a pathogen with little gene loss or gain, can generate biodiversity by rearranging its chromosome and altering gene expression (4, 36, 37) . For example, it has been reported recently (19) that an IS481 insertion could cause the differential expression of the TTSS cytotoxic effector protein BteA in clinical isolates of B. pertussis. This protein is expressed at higher levels in B. pertussis non-vaccine-type strains than in vaccinetype strains. This type-dependent expression suggests that the increased BteA protein level might play a key role in the type shift of B. pertussis (19) . It would be interesting to analyze if this mechanism could be involved in the expression switch of the TTSS between in vivo and in vitro conditions. Indepen-dently of the mechanism involved, the findings of this paper represent concrete evidence for an intuitively expected feature that has been described in other pathogens (15, 41, 43) : differential protein expression between bacteria grown under in vitro versus in vivo conditions. However, the outcome of our experiments is particularly relevant for the pertussis scenario, where the well-documented genomic divergence between vaccine strains (adapted to the laboratory) and bacteria recently isolated from the host (clinical isolates) might render control of the disease difficult. The in vivo/in vitro differences reported here add a new layer of complexity that should be taken into account in designing novel formulations, since current vaccines, based on strains subcultured extensively in vitro, might not reflect the real protein profile of the pathogen under in vivo conditions. with their derivatives obtained after 5 successive in vitro passages were resolved by 15% (wt/vol) SDS-PAGE, transferred to a PVDF membrane, and probed with a polyclonal serum specific for Bsp22. Samples were also probed with a polyclonal antiserum specific for subunit S1 of pertussis toxin (Ptx S1 ). Purified recombinant His 6 -Bsp22 and Ptx S1 proteins were included in this assay as positive controls.
FIG. 6. Analysis of TTSS expression in vivo. Protein samples obtained from B. pertussis supernatant cultures (in vitro) or from wholecell bacteria recovered from infected mice (in vivo) were analyzed for Bsp22 expression by immunoblotting. Samples obtained from Tohama I, Bp106 (Bp106 Not Adapted), and isolate Bp106 subjected to 35 in vitro passages (Bp106 Adapted) were probed with a polyclonal antiserum specific for Bsp22 or subunit S1 of pertussis toxin (Ptx S1 ). Purified His 6 -Bsp22 and Ptx were used as positive controls. 
